SPY448.15+0.27 0.06%
DIA349.02+0.20 0.06%
IXIC15,204.05+42.52 0.28%

BRIEF-Ayala Pharma To Present Clinical Data From Ongoing Phase 2 Accuracy Trial And New Preclinical Results From Combination Study Of AL101 At The European Society For Medical Oncology Virtual Congress 2021

reuters.com · 09/01/2021 08:28
BRIEF-Ayala Pharma To Present Clinical Data From Ongoing Phase 2 Accuracy Trial And New Preclinical Results From Combination Study Of AL101 At The European Society For Medical Oncology Virtual Congress 2021

- Ayala Pharmaceuticals Inc AYLA:

  • AYALA PHARMACEUTICALS TO PRESENT CLINICAL DATA FROM ONGOING PHASE 2 ACCURACY TRIAL AND NEW PRECLINICAL RESULTS FROM COMBINATION STUDY OF AL101 AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) VIRTUAL CONGRESS 2021

Source text for Eikon: ID:nGNX9gjmB3

Further company coverage: AYLA


(((Reuters.Briefs@thomsonreuters.com);))